[BIOMARKER ST2 AS A NEW PREDICTOR OF ACUTE KIDNEY INJURY IN PATIENTS WITH ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION].
Aim - to research sST2 level in risk of acute kidney injury after ST-elevation myocardial infarction (STEMI). 103 patients with STEMI, 75 (72.8%) male and 28 (27.2%) female at average age 61.85±12.23 years were enrolled. All the patients were divided to 2 groups according to AKIN classification: with creatinine dynamic more than 26.4 µmol/l (1st and more stage) and without those. Serum level of sST2, N-terminated pro-B-type natriuretic peptide (NT- proBNP ) determined by enzyme-like immunoassay at the 1st day of STEMI. Serum median level of sST2 in the 1st and 2nd groups were 128.62 [13.05-381.4] ng/ml and 54.7 [16.4-262.2] ng/ml accordantly (р = 0.0004). Biomarkers were determined in the serum of STEMI patients on baseline prognosed acute kidney injury (AKI) across 48 hours. sST2 level increase more than 36.4 ng/ml and NT- proBNP more than 1345 pg/ml prognosed AKI in patients with STEMI. sST2 in addition to NT- proBNP might be used as a main instrument of risk stratification of AKI development in patients with STEMI.